275
Assessed for eligibility

195
Randomized at Week 0

1 Patient randomized to placebo did not receive study drug

Placebo
N = 48

Discontinued study
N = 13
Lack of efficacy 5
Adverse event 3
Lost to follow-up 1
Protocol violation 2
Consent withdrawn 2

Completed Week 8
N = 35 (72.9%)

Tofacitinib 0.5 mg
BID
N = 31

Discontinued study
N = 11
Lack of efficacy 6
Adverse event 2
Lost to follow-up 0
Protocol violation 1
Consent withdrawn 2

Completed Week 8
N = 20 (64.5%)

Tofacitinib 3 mg
BID
N = 33

Discontinued study
N = 7
Lack of efficacy 5
Adverse event 0
Lost to follow-up 0
Protocol violation 0
Consent withdrawn 2

Completed Week 8
N = 26 (78.8%)

Tofacitinib 10 mg
BID
N = 33

Discontinued study
N = 2
Lack of efficacy 2
Adverse event 0
Lost to follow-up 0
Protocol violation 0
Consent withdrawn 0

Completed Week 8
N = 31 (93.9%)

Tofacitinib 15 mg
BID
N = 49

Discontinued study
N = 4
Lack of efficacy 1
Adverse event 2
Lost to follow-up 0
Protocol violation 1
Consent withdrawn 0

Completed Week 8
N = 45 (91.8%)